Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
Open Access
- 14 October 2008
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 20 (2), 244-250
- https://doi.org/10.1093/annonc/mdn638
Abstract
Background: Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC). The aim of this multicentre, open-label, phase IIIb study was to assess the addition of oxaliplatin to two different 5-FU regimens. Patients and methods: Patients with previously untreated mCRC were randomised to arm A [two-weekly oxaliplatin 85 mg/m2 + either continuous intravenous infusion (CIV) of 5-FU without LV or two-weekly bolus and CIV 5-FU + LV (LV5FU2)] or arm B (5-FU CIV or LV5FU2 alone). Irinotecan monotherapy was planned on progression. Results: A total of 725 patients were enrolled. After a fixed follow-up of 2 years for each patient, 2-year survival rates were 27.3% and 24.8% in arms A and B, respectively (hazard ratio 0.93; 95% confidence interval 0.78–1.10). The addition of oxaliplatin significantly improved response rates (54.1 versus 29.8%; P < 0.0001) and median progression-free survival (7.9 versus 5.9 months; P < 0.0001). The most common grade 3–4 toxic effects were neutropenia (arm A, 33%; arm B, 5%), diarrhoea (arm A, 14%; arm B, 8%), and fatigue (arm A, 9%; arm B, 8%). Conclusions: Despite improved rates of tumour control, these results failed to demonstrate a survival benefit from the addition of oxaliplatin to infused 5-FU and lend further support to the use of sequential monotherapy in some patients with mCRC.This publication has 24 references indexed in Scilit:
- Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysisThe Lancet Oncology, 2007
- Emerging therapies for rectal cancerColorectal Disease, 2006
- Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-AnalysisJournal of Clinical Oncology, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- The Evolution of Fluoropyrimidine Therapy: From Intravenous to OralThe Oncologist, 2001
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancersAnti-Cancer Drugs, 1997
- High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancerEuropean Journal of Cancer and Clinical Oncology, 1988